Ranbaxy laboratories today reported widening of its consolidated net loss to Rs1,029.72 crore for the third quarter ended December 31, 2014, as higher costs and foreign exchange losses hurt the embattled drug maker. The company had reported a net loss of Rs158.94 crore during the October-December period of previous fiscal. Net sales of the company declined to Rs2,587.59 crore compared to Rs2,858.96 crore during the same period of 2013-14, Ranbaxy laboratories said in a statement. Shares of the company fell one per cent on the BSE.